uniQure N.V. Foreign Currency Transaction Gain (Loss), Unrealized
uniQure N.V. (QURE) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$2.18 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-05-05
- uniQure N.V. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$2.18M, a 130.65% decline year-over-year.
- uniQure N.V. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$1.51M.
- uniQure N.V. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was -$629.00K, a 107.26% decline year-over-year.
- uniQure N.V. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-06-30 was $18.06M.
- uniQure N.V. foreign currency transaction gain (loss), unrealized for fiscal 2025 was $23.02M.
- uniQure N.V. foreign currency transaction gain (loss), unrealized for fiscal 2024 was -$15.41M, a 798.78% decline from fiscal 2023.
- uniQure N.V. foreign currency transaction gain (loss), unrealized for fiscal 2023 was $2.21M, a 90.01% decline from fiscal 2022.
- uniQure N.V. foreign currency transaction gain (loss), unrealized for fiscal 2022 was $22.08M, a 29.53% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$2.18M 10-Q · filed 2026-05-05 | -$3.69M derived: sum of 2 quarters · filed 2026-05-05 | -$4.32M derived: sum of 3 quarters · filed 2026-05-05 | $13.74M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$2.14M derived: sum of 2 quarters · filed 2026-03-02 | $15.91M derived: sum of 3 quarters · filed 2026-03-02 | $23.02M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$629.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $17.43M derived: sum of 2 quarters · filed 2025-11-10 | $24.53M 10-Q · filed 2025-11-10 | $3.39M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $18.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $25.16M 10-Q · filed 2025-07-29 | $4.02M derived: sum of 3 quarters · filed 2026-05-05 | $12.69M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $7.11M 10-Q · filed 2026-05-05 | -$14.04M derived: sum of 2 quarters · filed 2026-05-05 | -$5.37M derived: sum of 3 quarters · filed 2026-05-05 | -$6.92M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$21.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$12.47M derived: sum of 2 quarters · filed 2026-03-02 | -$14.03M derived: sum of 3 quarters · filed 2026-03-02 | -$15.41M 10-K · filed 2026-03-02 |
| 2024-09-30 | $8.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.12M derived: sum of 2 quarters · filed 2025-11-10 | $5.73M 10-Q · filed 2025-11-10 | $11.05M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$2.94M 10-Q · filed 2025-07-29 | $2.38M derived: sum of 3 quarters · filed 2026-03-02 | $210.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$1.39M 10-Q · filed 2025-05-09 | $3.94M derived: sum of 2 quarters · filed 2026-03-02 | $1.76M derived: sum of 3 quarters · filed 2026-03-02 | $2.01M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.15M derived: sum of 2 quarters · filed 2026-03-02 | $3.40M derived: sum of 3 quarters · filed 2026-03-02 | $2.21M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$1.93M derived: sum of 2 quarters · filed 2024-11-05 | -$3.12M 10-Q · filed 2024-11-05 | -$17.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $249.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$944.00K 10-Q · filed 2024-08-01 | -$15.25M derived: sum of 3 quarters · filed 2025-02-27 | -$3.35M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$1.19M 10-Q · filed 2024-05-07 | -$15.50M derived: sum of 2 quarters · filed 2025-02-27 | -$3.60M derived: sum of 3 quarters · filed 2025-02-27 | $13.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$14.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$2.41M derived: sum of 2 quarters · filed 2025-02-27 | $14.73M derived: sum of 3 quarters · filed 2025-02-27 | $22.08M 10-K · filed 2025-02-27 |
| 2022-09-30 | $11.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $29.03M derived: sum of 2 quarters · filed 2023-11-07 | $36.39M 10-Q · filed 2023-11-07 | $44.48M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $17.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $24.49M 10-Q · filed 2023-08-01 | $32.58M derived: sum of 3 quarters · filed 2024-02-28 | |
| 2022-03-31 | $7.36M 10-Q · filed 2023-05-09 | $15.45M derived: sum of 2 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $31.34M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $23.24M 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | -$14.73M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |